Agenus to present agen1181 clinical data at sitc

Lexington, mass., oct. 01, 2021 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced acceptance of its abstract describing updated phase 1 clinical trial results for agen1181 (fc-enhanced anti-ctla-4) alone and in combination with balstilimab (anti-pd-1) at the society for immunotherapy of cancer (sitc) 36th annual meeting, to be held november 10-14, 2021.
AGEN Ratings Summary
AGEN Quant Ranking